Clozapine is an atypical antipsychotic with particular efficacy in schizophrenia, possibly related to potentiation of brain N-methyl-D-aspartate receptor (NMDAR) -mediated neurotransmission. NMDARs are regulated in vivo by glycine, which is regulated in turn by glycine transporters. The present study investigates transport processes regulating glycine uptake into rat brain synaptosomes, along with effects of clozapine on synaptosomal glycine transport. Amino-acid uptake of amino acids was assessed in rat brain P2 synaptosomal preparations using a radiotransport assay. Synaptosomal glycine transport was inhibited by a series of amino acids and by the selective System A antagonist MeAIB (2-methylaminoisobutyric acid). Clozapine inhibited transport of both glycine and MeAIB, but not other amino acids, at concentrations associated with preferential clinical response (0.5-1 lg/ml). By contrast, other antipsychotics studied were ineffective. The novel glycine transport inhibitor Further, in meta-analytic studies, clozapine effect sizes are approximately double those of other agents. 4, 5 Several theories have been proposed to account for the unique clinical effects of clozapine. These include preferential binding to serotonin (5-HT2A) receptors, 6 D4 selectivity, 7 or weak binding to D2 receptors with fast dissociation kinetics.
Clozapine is a widely used antipsychotic for the treatment of schizophrenia. Up to 20% of patients respond preferentially to clozapine over other agents. 1 Further, significant improvement in neurocognitive neurophysiological, social, and occupational functioning is observed during long-term clozapine treatment. 2 Several new antipsychotics have been introduced over recent years that, like clozapine, have an associated decreased risk of extrapyramidal side effects (EPS). Nevertheless, evidence for effectiveness of clozapine in treatment-resistant schizophrenia remains stronger than for other agents. 1, 3 Further, in meta-analytic studies, clozapine effect sizes are approximately double those of other agents. 4, 5 Several theories have been proposed to account for the unique clinical effects of clozapine. These include preferential binding to serotonin (5-HT2A) receptors, 6 D4 selectivity, 7 or weak binding to D2 receptors with fast dissociation kinetics. 8 However, these theories propose to account only for the decreased risk of extrapyramidal side effects associated with clozapine and other atypical antipsychotics, not for its preferential efficacy. Other newer atypicals, including risperidone and olanzapine, each share at least some of the above properties with clozapine. While these agents, like clozapine, have reduced risk of EPS, they do not appear to share clozapine's differential therapeutic efficacy, particularly against negative symptoms. Clozapine treatment typically produces trough plasma levels in the range of 0.2-1.2 mg/ml during therapeutic treatment, 9 with preferential response to clozapine being associated with plasma concentrations of approximately 0.5 mg/ml or greater in both cross-sectional 10 and longitudinal 11 studies. Two active metabolites of clozapine, desmethyl clozapine and clozapine-N-oxide, have also been described and may contribute to clinical response. 9 Concentrations of clozapine in brain are approximately 24-fold higher than in serum, although brain concentrations of clozapine metabolites are minimal. 12 At brain concentrations associated with clinical treatment, clozapine occupies D2 receptors to a similar degree as other atypical antipsychotics. Further, clozapine saturates 5-HT2A receptors in vivo at doses far lower than those required to achieve optimal therapeutic effects, leading to the hypothesis that low dopamine occupancy alone is sufficient to account for the reduced risk of EPS associated with clozapine treatment. 8 Nevertheless, since doses of other antipsychotics can also be manipulated to give the same degree of D2 receptor occupancy (60-80%) as is observed during clozapine treatment, D2 occupancy cannot account for differential efficacy for treatment of refractory symptoms among antipsychotics.
Over recent years, increasing attention has been paid to N-methyl-D-aspartate (NMDA)-based models of schizophrenia. [13] [14] [15] One potential explanation for the preferential efficacy of clozapine is its ability to potentiate NMDA receptor-mediated neurotransmission. Thus, clozapine has been shown to modulate NMDA responses in frontal cortex slices in vitro 16, 17 and to prevent PCP-induced NMDA receptor hyperactivity in vivo.
18 Clozapine-induced potentiation of excitatory synaptic responses in the perforant pathdentate gyrus pathway in rabbits is similarly reversed by the NMDA antagonist MK-801. 19 Clozapine, but not haloperidol, reverses discriminative stimulus effects of noncompetitive NMDA antagonists in rodents, 20 and PCP-induced deficits in prepulse inhibition in rodents 21 and primates. 22 Clozapine, but not risperidone, also reverses ketamine-induced alterations in regional cerebral blood flow in rodents 23 and PCP-induced cognitive deficits in monkeys. 24 In patients with schizophrenia, clozapine uniquely blunts ketamine-induced exacerbation of psychosis. 25 At present, mechanisms whereby clozapine might potentiate NMDA receptor-mediated neurotransmission are unknown. NMDA receptors contain sites for glutamate, glycine/D-serine and polyamines. Evidence is lacking for direct clozapine interaction with the NMDA complex, although such interaction has not been rigorously excluded. Alternatively, clozapine may modulate NMDA receptor activation indirectly, by modulation of synaptic levels of glutamate, glycine or D-serine.
Indirect supportive evidence has been obtained for each of these possibilities. In the case of glutamate, a switch from olanzapine to clozapine was found to lead to a significant increase in serum glutamate levels in 11 patients studied, and increase in brain glutamate levels in patients showing beneficial clinical response. 26 Similar increases in serum glutamate levels are observed in patients treated with clozapine vs typical antipsychotics. 27 Finally, clozapine treatment has also been shown to downregulate glutamate transporter expression in rodents, 28 also suggestive of modulation of brain glutamate levels.
In the case of glycine and D-serine, effects of clozapine on transport or metabolism have not been directly studied. Nevertheless, it has been observed clinically that these agents (glycine and D-serine) are effective in treatment of schizophrenia when combined with typical or newer atypical antipsychotics, 29 but may be less effective in the presence of clozapine. 30, 31 Further, the partial antagonist D-cycloserine significantly improves symptoms of schizophrenia when combined with either typical 32, 33 or newer atypical 34, 35 antipsychotics, but paradoxically worsens symptoms when combined with clozapine. 36 
D-
Cycloserine functions as a net NMDA agonist in the presence of low endogenous glycine-site occupancy, but a net antagonist in the presence of high endogenous occupancy concentrations. 37 A parsimonious explanation, therefore, is that clozapine may function by effectively increasing glycine-site occupancy, leading both to direct amelioration of negative symptoms and decreasing effectiveness of added NMDA agonists.
Brain transporters responsible for modulation of synaptic glycine and D-serine levels remain to be definitively identified. Much recent work has implicated glycine type 1 (GLYT1) transporters, [38] [39] [40] which are expressed primarily in glia. 41 However, classical studies of amino-acid transport suggest the existence of multiple systems capable of transporting glycine, including not only glycine, but also System A, transporters. 42 System A, like system Gly, is inhibited by the glycine derivative N-methylglycine (sarcosine). Thus, sarcosine sensitivity, which differentiates, GLYT1 from GLYT2 transporters, cannot be used to differentiate GLYT1 vs System A-mediated transport. More recently, high-affinity GLYT1 transport inhibitors, such as N[3-(4 0 -fluorophenyl)-3-(4 0 -phenylphenoxy)propyl]sarcosine (NFPS), 43 have been developed. These compounds show nanomolar level affinity against GLYT1 transporters, 44,45 but are not yet generally available for pharmacological research.
System A is distinguished from other transport systems by sensitivity to inhibition by the synthetic amino-acid derivative 2-methyl aminoisobutyric acid (MeAIB). Unlike GLYT1 transporters, System A transports a variety of small, neutral amino acids. Several System A-family transporters have recently been cloned, and shown to belong to the sodiumcoupled neutral amino-acid (SNAT) family of transporters. 46 Both SNAT1 and SNAT2 receptors are found in neurons, with SNAT1 transporters showing relative specificity for glutamine, and SNAT2 transporters showing broader substrate specificity with high affinity for glycine and other small amino acids (eg, proline). The SNAT family also contains system N transporters, which are differentiated from System A transporters by insensitivity to MeAIB and ability to function as obligate exchangers. 47, 48 Although system A transporters were once thought to provide glutamine precursor for neurotransmitter glutamate synthesis, more recent studies suggest that other transporters, such as System N b , may be more critical. 49 Although there is widespread appreciation that NMDA synapses in brain areas such as cortex and striatum are 'protected' from circulating glycine levels by glycine transporters, the identity of the processes providing this protection remains to be determined. Because synapses represent a protected subcompartment in brain, synaptic concentrations cannot be directly measured. However, synaptosomes constitute a brain preparation enriched in presynaptic terminals, making them an ideal preparation in which to investigate potential transport processes involved in amino-acid regulation. Only one previous study has investigated amino-acid sensitivity of glycine uptake in synaptosomes from cortex or cerebellum, 42 and no prior study has evaluated interaction of clozapine with amino-acid transport processes. The present study investigates both the transport processes responsible for glycine transport in synaptosomes as well as the sensitivity of these processes to inhibition by therapeutically relevant concentrations of clozapine.
Materials and methods

Radiotransport assay
GLY uptake assays were conducted using methods similar to those used previously. 42, 50 Synaptosomal P 2 fractions were prepared from cerebral cortex þ hippocampus of Sprague-Dawley rats (200-250 g). Brain tissue was homogenized in 0.32 M sucrose in Tris-HCl buffer (pH 7.4), and centrifuged at 1 000 Â g for 10 min at 41C in a Sorvall 5C centrifuge. The supernatant was then centrifuged at 14 000 Â g for 10 min and the pellet resuspended in artificial CSF having the following composition (mM): NaCl, 125; KCl, 3; MgSO 4 , 1.2; CaCl 2 , 1.2; NaH 2 PO 4 , 1; NaHCO 3 , 22; glucose, 10. Homogenate was aerated with 95% O 2 /5% CO 2 until use. A volume of 1 ml aliquots of homogenate were preincubated with specific concentrations of amino acids and antipsychotics as indicated, following which uptake was initiated by the addition of indicated concentrations of tritiated amino acids (Dupont/NEN or Sigma). Clozapine and metabolites were solubilized in 0.9% cyclodextrin and adjusted to pH 7.0. Drugs were obtained from Sigma (St Louis, MO, USA), except for NFPS, which was a gift from Egis Pharmaceuticals (Budapest, Hungary). Nonspecific uptake was determined in the presence of 30 mM sarcosine for glycine and MeAIB uptake studies, and 10 mM L-PDC for glutamate, 10 mM nipecotic acid for GABA, and 30 mM sarcosine for other amino acids.
For assays with C6 glioma cells (American Type Culture Collection, Manassas, VA, USA), cells were cultured in Kaighn's modification of Ham's F12 K media with 2 mM L-glutamine modified by ATCC to contain 1.5 g/l sodium bicarbonate supplemented with 15% horse serum, 2.5% fetal bovine serum, 100 U/ml penicillin and 100 mg/ml streptomycin. Cells were seeded in 24- 
Radioreceptor assay
Extensively washed crude synaptic membranes were prepared as described previously. 51 Cerebral cortex plus hippocampus from male Sprague-Dawley rats (150-250 g) were rapidly removed and homogenized in 15 v/w ice-cold 0.32 M sucrose using a Teflon-glass homogenizer at 800 rpm. Homogenate was centrifuged at 1000 Â g for 10 min in a Sorvall RC-5B refrigerated centrifuge. Supernatant was decanted and recentrifuged at 20 000 Â g for 20 min. The resulting pellet was resuspended in 30 v/w deionized water using a Brinkman Polytron, setting 6; the resulting suspension was centrifuged at 8000 Â g for 20 min. The supernatant and buffy coat were decanted and centrifuged at 48 000 Â g for 20 min. The pellet was then resuspended in 5 mM EDTA buffered to pH 7.4 by the addition of Tris base (approximately 15 mM) and incubated for 1 h at 371C. Following incubation, the membrane suspension was again centrifuged at 48 000 Â g for 20 min. Pellets were then frozen at À41C for 1-14 days. On the day of the experiment, frozen pellets were thawed and suspended in 30 v/w deionized water for 1 h at 371C. The membrane suspension was recentrifuged for 20 min at 48 000 Â g. Pellets were then washed three times by resuspension in 30 v/w deionized water and centrifugation at 48 000 Â g. Following final centrifugation, pellets were suspended in 150 v/w 5 mM Tris-acetate buffer adjusted to pH 7.4.
A volume of 1 ml aliquots (100-200 mg protein) of homogenate were incubated with specified concentrations of [ For both radiotransport and radioreceptor assays, incubations were terminated by filtration under reduced pressure using a 24-well cell harvester (Brandel Corp, Gaithersburg, MD, USA) and Whatman GF/B filters. Filter disks were placed in vials containing 4 ml Hydrofluor (National Diagnostics, Manville, NJ, USA) and counted with a scintillation counter at a counting efficiency of 50%.
One-site vs two-site fits were evaluated for displacement curves by ANOVA using the Graphpad PRISM 4.0 (Graphpad USA). Results of one-site fits are reported unless otherwise indicated. Two-tailed statistics were used throughout, with preset alpha level of significance of Po0.05. Data in text represent mean7SEM.
Results
Amino-acid sensitivity of synaptosomal amino-acid transport In order to evaluate transport processes responsible for glycine transport in synaptosomes, potency of a series of amino acids and derivatives was evaluated.
As expected, at a concentration of 1 mM, glycine and N-methylglycine (sarcosine) proved most effective. However, significant, 450% inhibition was observed as well for a series of other small neutral amino acids, including glutamine, proline, leucine, serine, and cysteine ( Figure 1a) . The selective System A antagonist MeAIB inhibited transport by approximately 40% at a concentration of 1 mM. In contrast, the selective system L antagonist, BCH (2-amino bicyclo (2,2,1) heptane-2 carboxylic acid), the GLYT2 inhibitor balanine and the basic amino-acid lysine were only marginally effective (o25% inhibition) at concentrations of 1 mM, while arginine, GABA, and taurine were all ineffective. Synaptosomal glycine transport was fully inhibited by 30 mM concentrations of glutamine, proline, serine, MeAIB, leucine or sarcosine (Figure 1b) .
Across amino acids, the rank order of potency in synaptosomal membranes correlated significantly with published rank order of potency at SNAT2-type System A transporters 52 ( Figure 2 ), but not that of other cloned system A transporters. 53, 54 Effect of clozapine and other atypical antipsychotics on synaptosomal amino-acid transport In order to evaluate potential effects of clozapine on synaptosomal glycine uptake, membranes were incubated with clozapine at concentrations corresponding to those observed in plasma and brain during clozapine treatment. Clozapine inhibited glycine transport in a dose-dependent fashion (Figure 3 ). Significant inhibition of glycine transport was observed beginning at a dose of 0.1 mg/ml. At concentrations corresponding to plasma levels associated with preferential response to clozapine (0.5-1.0 mg/ml), clozapine induced a 5-15% inhibition of glycine transport. Higher concentrations led to complete inhibition of uptake.
At concentrations associated with brain levels of clozapine during clinical treatment (10-20 mg/ml), 450% uptake inhibition was observed. In contrast to clozapine, other antipsychotics tested did not inhibit glycine transport even at concentrations substantially higher than those observed in plasma during treatment (Table 1) .
Effect of clozapine on synaptosomal transport of MeAIB and other nonglycine amino acids In order to evaluate the degree to which the inhibition of glycine transport was due to an effect mediated at (Figure 4) . Also, as with glycine transport, a second phase of inhibition was observed at clozapine concentrations of 5.0-50 mg/ml. In the presence of a saturating concentration of the System A (but not GlyT1 substrate) glutamine, clozapine had no significant effect on synaptosomal [ 3 H]MeAIB uptake at concentrations of 0.1-10 mg/ml ( Table 2) .
The ability of clozapine to inhibit the transport of other amino acids of interest was also evaluated. At a concentration of 1 mg/ml, clozapine did not significantly inhibit transport of glutamate, glutamine, Dserine or other small neutral amino acids, and led to a paradoxical increase D-serine transport. At a somewhat higher concentration (5-10 mg/ml), significant inhibition of other System A ligands, including alanine, proline, glutamine and glutamate was observed ( Figure 5 ).
Effect of NFPS on synaptosomal glycine and MeAIB binding
In order to evaluate the relative contributions of GlyT1 and System A transporters on synaptosomal glycine transport, studies were performed with the selective GLYT1 antagonist NFPS ( Figure 6 
Effect of clozapine on [ 3 H]MeAIB transport in cell culture
Because cloned transporters were not available for the present study, a final study was performed in a cell Figure 1 ) and published percent inhibition values for inhibition of uptake by cloned SNAT2 transporters. 52 Lines represent regression795% confidence interval. line, rat C6 glioma cells, that are known to express ATA2 transporters endogenously. 55 As with brain synaptosomal transport, clozapine inhibited [ 3 H]MeAIB significantly in a dose-dependent fashion at concentrations between 0.5 and 1.0 mg/ml ( Figure  8 ). In C6 glioma cells, only 20% of specific [ 3 H]MeAIB uptake was inhibited by clozapine, suggesting the existence of other, nonclozapine-sensitive System A transporters.
Effect of clozapine on NMDA binding
In order to further evaluate an alternative mechanism whereby clozapine might potentiate NMDARmediated neurotransmission, binding assays were conducted using [ 
Discussion
Schizophrenia is associated with disturbances not only of dopaminergic, but also of glutamatergic, neurotransmission. Recent clinical findings with NMDA/glycine-site agonists has renewed interest in brain systems regulating glycine homeostasis in vivo, with particular recent focus on GLYT1 transporters as regulators of synaptic glycine levels and NMDA receptor-mediated neurotransmission. Although recent studies support a role of GLYT1 transporters in glycine homeostasis, it remains an open question as to whether additional transporters may also modulate synaptic glycine levels, and whether such transporters may also serve as potential therapeutic targets. Glycine transport inhibition by clozapine DC Javitt et al
The major findings of the present study are twofold. First, that glycine transport in isolated forebrain synaptosomes is mediated not only by GLYT1 transporters, but also by System A, and, second, that System A transport, in particular, may be sensitive to inhibition by therapeutic concentrations of clozapine, potentially contributing to the unique therapeutic effectiveness of this agent.
Since appreciation of the role of glycine transport in modulation of brain NMDA receptors, attention has focused primarily on type 1 glycine (GLYT1) transporters. As opposed to type 2 (GLYT2) transporters, GLYT1 transporters are located in forebrain regions with prominent NMDA receptor distribution, 39 making them well suited to regulate forebrain glycine levels. Further, GLYT1 transporters coexpressed with NMDA receptors in Xenopus oocytes show ability to regulate activity of coexpressed NMDA receptors. 38 However, as opposed to GLYT2 transporters which are neuronally localized, GLYT1 transporters are localized to glia, [56] [57] [58] especially those grown in apposition to neurons. 56 The non-neuronal localization of GLYT1 transporters raises the question of whether alternative, neuronally localized transporters may also participate in regulation of synaptic glycine levels.
The majority of studies of glycine transport over the past decade have used transporters expressed either in cell culture 59, 60 or Xenopus oocytes, 38, 61, 62 with few studies using native transporters to investigate endogenous regulatory mechanisms. For the present study, P2 synaptosomes were prepared from native rat brain membranes to permit study of endogenous transport processes. Synaptosomes are enriched in presynaptic terminals and in 'feet' of perisynaptic glia and thus provide the closest estimate of processes that may be implicated in synaptic glycine regulation. Few previous studies have investigated amino-acid transport processes in synaptosomes, as opposed to whole brain or brain slices, which primarily reflect glial and somatodendritic transport processes. One previous study examined amino-acid sensitivity of cortical synaptosomal glycine transport 42 and, like the present study, demonstrated significant inhibition of transport by System A ligands such as proline, histidine, glutamine and MeAIB. A similar study using hippocampal membranes found sensitivity to Lserine, L-glutamate, L-proline, histidine, 63 agents that inhibit system A but not GLYT1-mediated transport. Thus, the finding in the present study of system A sensitivity of synaptosomal glycine uptake is consistent with extant literature in the field.
Of note, while sarcosine (N-methylglycine) is often considered a selective inhibitor of GLYT1 transporters, this is true only relative to GLYT2. In this study as in previous studies, System A-dependent transport was fully inhibited by sarcosine. In contrast, MeAIB does indeed appear to serve as a selective System A inhibitor and does not inhibit glycine transport by cloned GLYT1 transporters. 58 Thus, the demonstration in the present study that MeAIB substantially inhibits synaptosomal glycine transport argues strongly for a role of System A transporters. The rank order of potency with which amino acids and derivatives inhibited transport also permits tentative identifications to be made concerning the identity of the System A transporter involved in synaptosomal glycine transport, based upon comparison with cloned transporters.
NFPS studies
Because 'classical' inhibitors such as sarcosine and MeAIB are somewhat nonselective, it is difficult to estimate proportionate contributions of the different transport systems in glycine uptake from those studies alone. However, studies with the newer GLYT1 selective antagonist NFPS show a clear biphasic pattern, with approximately 40% of transport being inhibited by nanomolar NFPS levels, representing the GLYT1 contribution to transport. At higher, micromolar levels, NFPS displaced the remaining 60% of sarcosine-sensitive transport. Micromolar levels of NFPS inhibited MeAIB transport as well, suggesting first that NFPS has a low-affinity interaction with system A that should be considered in psychopharmacological studies and, second, that the remaining transport reflects system A activity.
SNAT transporter family System A transporters belong to the sodium-coupled neutral amino acid (SNAT) family of transporters, which are the products of the SLC38 gene. 46 These transporters show homology with the vesicular inhibitory amino-acid transporter, and are divided into two broad categories based upon sensitivity to MeAIB and the need for proton cotransport. System A transporters are MeAIB sensitive and nonproton sensitive. In contrast, System N transporters, which primarily transport glutamine in astrocytes, are MeAIB insensitive and proton sensitive. Three members of the System A subfamily (SNAT1, 2 and 4) have been cloned to date, and are differentiated based upon distribution and sensitivity to proline. Both SNAT1 (also known as ATA1, GInT, NAT2, SA2, SAT1) and SNAT2 (also known as ATA2, KIAA1382, SA1, SAT2) are present in the brain. Although the amino-acid dependencies of these transporters is similar, SNAT2 transporters transport a wider range of substrates and, in particular, show high affinity transport of both glycine and proline.
In the present study, the rank order of inhibition of synaptosomal glycine transport by a range of amino acids closely resembled published rank orders for inhibition of SNAT2 transporters, 64 suggesting that SNAT2 transporters may be primarily responsible for synaptosomal glycine transport. Similar results are obtained if other published rank orders of potency are used. 48, 64 Finally, immunocytochemical studies have demonstrated presence of SNAT2 transporters in axons of cultured hippocampal neurons, 65 confirming the appropriate anatomical localization of these transporters for regulation of presynaptic glycine transport. SNAT1 proteins, which are also present in cultured hippocampal neurons, appear not to be present in axon terminals in mature brain. 66 Subcellular localization of SNAT2 transporters is not known at present, although it is found primarily in regions of the brain with high concentrations of glutamate neurons. 64 SNAT3 transporters, which are found in astrocytic processes surrounding axonal terminals, may also participate in regulation of synaptic glycine levels. 66 Interestingly, although system A strongly contributes to overall brain glutamine, and also alanine, transport and for incorporation of glutamine and alanine into the metabolic glutamate pool, it does not appear to be responsible for transport of glutamine and/or alanine involved in the neurotransmitter glutamine/glutamate pool. Instead, such transport appears to be mediated by a yet-unidentified histidine-sensitive, MeAIB-insensitive transporter. 49 This is consistent with the finding in the present study that synaptosomal glutamine and alanine transport was less sensitive to inhibition by clozapine than was glycine transport. Thus, although system A has received the greatest attention with regard to its role in glutamine transport, it is quite possible that the physiological contributions of system A transporters, and especially of the SNAT2 subtype, relate to transport of other amino acids, especially glycine.
Clozapine effects
A second finding of the present study is that the atypical antipsychotic clozapine significantly inhibited synaptosomal glycine transport at concentrations analogous to those found in plasma and/or brain during clozapine treatment. Plasma clozapine levels 9 associated with preferential clozapine treatment are in the range of 0.5-1.0 mg/ml. At these concentrations, clozapine significantly inhibited both glycine and MeAIB transport in brain synaptosomes, as well as MeAIB transport in cells known to express SNAT2 transporters. In synaptosomes, full inhibition of glycine and MeAIB was not observed until concentrations significantly higher than those observed during clinical treatment were used, and clozapine inhibited transport of other SNAT2-transporter ligands only at concentrations higher than those needed to inhibit glycine transport. However, in the presence of NFPS, biphasic blockade of [ 3 H]glycine uptake by clozapine was observed, with high-affinity inhibition occurring at concentrations substantially below 1 mg/ml. Similarly, in C6 glioma cells, although only a portion of sarcosine-sensitive MeAIB transport was inhibited by clozapine, the inhibition occurred over the 0.5-1.0 mg/ml. These findings raise the possibility that multiple SNAT2 subpopulations with differing affinities for clozapine, may be represented in brain synaptosomal compartments.
Glycine transport inhibitors
Although regulation of glycine transport is a relative new strategy for modulation of endogenous NMDA transmission, several recent preclinical studies with glycine transport inhibitors have yielded encouraging results. Initial studies were performed with glycyldodecylamide (GDA), a compound that reversed behavioral effects of the NMDA antagonist PCP in rodents, 67, 68 which was subsequently shown to inhibit glycine uptake in synaptosomes. 69, 70 More recent studies have been performed using NFPS or other high-affinity glycine transport inhibitors such as Org 24598. 71 NFPS blocks glycine transport in cloned GLYT1 transporters and rat brain synaptosomes with an affinity of approximately 10 nM. 44, 45, 72, 73 NFPS potentiates NMDA transmission in rat hippocampal slices, 74 in vivo hippocampus, 75 and in rat prefrontal cortex in vivo. 76 In behavioral screens, NFPS shows antipsychotic effectiveness profile as reflected in ability to reverse PCP-induced hyperactivity 44 and enhance prepulse inhibition of the acoustic startle reflex in DBA/2 mice, 75 as well as ability to stabilize in vivo dopamine release in PCP-treated rats. 77 Those studies strongly support the initial conjecture regarding the importance of glycine transport to NMDA regulation. The present findings suggest that GLYT1 transporters may not play an exclusive role in glycine modulation, but that other brain transport processes may also be important and may contribute to therapeutic effectiveness of clozapine.
As opposed to GLYT1 transporters, which show very limited substrate specificity, System A transporters contribute to overall brain metabolism in addition to transporting glycine. Thus, for example, both SNAT1 and SNAT2 transporters are electrogenic, with transport being associated with neuronal depolarization. 54 SNAT transporters also transport precursors of glutathione, 66 a compound that is reported to be reduced in CSF of individuals with schizophrenia. 78 Finally, SNAT2 transporters also play a critical role in transporting specific amino acids, including glycine and proline, out of brain across the blood-brain barrier. 79 Given the nonspecific role of SNAT2 transporters in amino-acid homeostasis, inhibition of SNAT2 may not be the preferred method for raising glycine levels, but may merely be a fortuitous cross-reactivity of clozapine that contributes to its unique clinical profile, but may also contribute to well-known clozapine side effects, such as epileptogenicity. 80 Clarification of the role of SNAT2 transporters in the regulation of synaptic neurotransmission in vivo will thus have to await synthesis of high-affinity System A transport inhibitors.
In summary, the demonstration of glycinergic regulation of NMDA neurotransmission in the 1980s, coupled with more recent demonstration of potential therapeutic effectiveness of glycinergic agents in neuropsychiatric disorders such as schizophrenia, has provided new impetus for investigation of brain mechanisms underlying NMDA regulation in vivo. A significant focus in recent years has been on GLYT1 transporters in forebrain and GLYT2 transporters in hindbrain and cerebellum. The present study suggests, however, that System A may be of considerable importance as well in regulation of synaptic glycine levels, and that a specific interaction of clozapine with System A transporters may contribute to its unique mechanism of action. Coupled with recent advances in molecular biology of System A transporters, this finding may provide new avenues for research into basic biological mechanisms underlying schizophrenia.
